MED
Medifast·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
Price Hits 52-week Low
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MED
Medifast, Inc.
A manufacturer of weight and disease management products and other health and diet products
Healthcare Providers and Services
--
08/25/2006
New York Stock Exchange
504
12-31
Common stock
100 International Drive, Baltimore, Maryland 21202
--
Medifast, Inc., was incorporated in Delaware in 1989. The Company operates primarily through five wholly owned subsidiaries, Jason Pharmaceuticals Inc., Take Shape For Life Inc., Jason Enterprises Inc., Jason Properties LLC and Seven Crondall LLC. Its business is the production, distribution and sale of weight management and disease management products and other health and dietary consumables. Its product line includes weight and disease management, meal substitutes and vitamins, which are primarily produced at an FDA-approved modern factory in Owings, Maryland.
Earnings Call
Q1/2025
Estimate EPS-0.25
Actual EPS-0.07
Estimate Revenue116.40M
Actual Revenue115.73M
Medifast's Q1 2025 Earnings Call: Unraveling Contradictions in Coach Productivity, GLP-1 Impact, and Marketing Strategies
May 02,2025 12:49
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.22
Actual EPS0.22
Estimate Revenue101.80M
Actual Revenue105.60M
Medifast's Q2 2025: Navigating Contradictions in Coach Productivity, Marketing Strategy, and GLP-1 Integration
Aug 05,2025 12:05
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.36
Actual EPS-0.21
Estimate Revenue89.70M
Actual Revenue89.40M
Medifast's Q3 2025 Earnings Call: Contradictions in Metabolic Focus, GLP-1 Impact, and Coach Productivity
Nov 03,2025 06:56
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MED has released its 2025 Q3 earnings. EPS was reported at -0.21, versus the expected -0.36, beating expectations. The chart below visualizes how MED has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MED has released its 2025 Q3 earnings report, with revenue of 89.41M, reflecting a YoY change of -36.21%, and net profit of -2.26M, showing a YoY change of -300.27%. The Sankey diagram below clearly presents MED's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
